Back

Identification a Compact Promoter using a New Promoter Selection Strategy and Engineering Hybrid Pol II/III Enable Efficient Genome Editing in Human Retinal Ganglion Cells

Zhang, P.; Zhang, S. H.; Chang, Y.-Y.; Li, S.; Fan, L.; Li, W.; Duan, Y.; Cheng, J.; Keuthan, C.; Berlinicke, C. A.; Welsbie, D. S.; Zack, D. J.

2026-01-28 molecular biology
10.64898/2026.01.26.701896 bioRxiv
Show abstract

Promoters and vectors are critical components of gene therapy, enabling the delivery and expression of therapeutic genes to correct both loss- and gain-of-function mutations. Adeno-associated virus (AAV) vectors are the leading platform for in vivo gene delivery; however, the widely used Streptococcus pyogenes Cas9 (SpCas9, 4.1 kb) approaches the AAV packaging limit of 4.7 kb. This constraint often necessitates dual-vector systems, which reduce therapeutic efficiency, or the use of smaller nucleases such as SaCas9 (3.2 kb) and AacCas12b (3.4 kb), which have lower PAM site frequencies. To enhance promoter selection for gene therapy applications, we developed a strategy to identify compact, cell-preferred RNA polymerase II (Pol II) promoters. Analysis of approximately 300 compact Pol II promoters revealed that exogenous expression levels in one cell type correlate more strongly with those in other cell types than with endogenous expression, underscoring the importance of exogenous expression efficiency in promoter selection. Using this approach, we identified a compact Pol II promoter #2 (Pro2, 133 bp) that drives robust transgene expression in human retinal ganglion cells (RGCs). To enable single-AAV delivery of SpCas9, we analyzed three commonly used Pol III promoters (H1, 7SK and U6) and determined their minimal functional lengths using a CRISPR/Cas9 reporter assay. We further engineered three compact hybrid Pol II/III promoters which combined pro2 with minimal H1, 7SK and U6 (276, 294, and 323 bp) capable of co-expressing SpCas9 and gRNA, enabling efficient genome editing in both transfected HEK293 cells (approaching 100%) and human RGCs (up to 55.9%) from human stem cell-derived retinal ganglion cells (RGCs). Together, these findings establish a framework for developing single-AAV CRISPR-based gene therapy strategies. Authors contributionsPWZ and DJZ conceived the study, designed the experiments, performed data analysis and interpretation, and were the primary contributors to manuscript writing. STZ played a key role in data collection and correlation analysis. YYC, SL, LF, CJK, YD, CAB, JC, and DW contributed to the execution of essential experiments and subsequent data analysis. All authors have read and approved the final manuscript. Declaration of interestsThe authors declare no conflicts of interest.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Molecular Therapy
71 papers in training set
Top 0.1%
26.5%
2
Molecular Therapy - Methods & Clinical Development
38 papers in training set
Top 0.1%
12.6%
3
Nature Communications
4913 papers in training set
Top 25%
7.0%
4
Molecular Therapy Nucleic Acids
32 papers in training set
Top 0.1%
6.5%
50% of probability mass above
5
Molecular Therapy - Nucleic Acids
24 papers in training set
Top 0.1%
5.0%
6
eLife
5422 papers in training set
Top 39%
1.8%
7
The CRISPR Journal
33 papers in training set
Top 0.1%
1.7%
8
Translational Vision Science & Technology
35 papers in training set
Top 0.4%
1.5%
9
Frontiers in Bioengineering and Biotechnology
88 papers in training set
Top 2%
1.5%
10
Molecular Therapy Methods & Clinical Development
13 papers in training set
Top 0.1%
1.4%
11
Nucleic Acids Research
1128 papers in training set
Top 12%
1.4%
12
Protein & Cell
25 papers in training set
Top 1%
1.4%
13
Cell Reports Medicine
140 papers in training set
Top 5%
1.3%
14
Scientific Reports
3102 papers in training set
Top 66%
1.3%
15
ACS Synthetic Biology
256 papers in training set
Top 2%
1.3%
16
Genome Medicine
154 papers in training set
Top 6%
1.3%
17
Advanced Science
249 papers in training set
Top 15%
1.0%
18
PLOS ONE
4510 papers in training set
Top 64%
0.9%
19
Communications Biology
886 papers in training set
Top 18%
0.9%
20
Molecular Cancer
14 papers in training set
Top 0.7%
0.9%
21
Human Molecular Genetics
130 papers in training set
Top 3%
0.8%
22
PLOS Biology
408 papers in training set
Top 18%
0.8%
23
Cell Reports Methods
141 papers in training set
Top 4%
0.8%
24
Cell Genomics
162 papers in training set
Top 6%
0.8%
25
JCI Insight
241 papers in training set
Top 7%
0.8%
26
Cell Proliferation
12 papers in training set
Top 0.4%
0.8%
27
Cell Discovery
54 papers in training set
Top 5%
0.7%
28
Science Advances
1098 papers in training set
Top 30%
0.7%
29
NAR Molecular Medicine
18 papers in training set
Top 0.3%
0.7%
30
Small Methods
26 papers in training set
Top 1%
0.7%